Form 13-F position report

ACASTI PHARMA INC

Reported by MORGAN STANLEY

ACST CUSIP 00430K873 Manager CIK 0000895421

Reported 11,295 shares, unchanged from the prior quarter.

Reported value -5.7%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value < 0.01% This manager · Q4 2022
Shares 11,295 Quarter-end amount reported
Reported value $5,659 Fair value at quarter end
Consecutive quarters held 6 Through Q4 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 42000
2022-03-31 66000
2022-06-30 16000
2022-09-30 6000
2022-12-31 5659
2023-03-31 5195
2023-06-30 5931
2023-09-30 5239
2023-09-30 0
2023-12-31 5439
2024-03-31 6445
2024-06-30 5495
2024-09-30 5646
2024-12-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

14 quarters
Quarterly reported position history for ACASTI PHARMA INC held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2024 Reduced 0 -1,882 (-100.0%) 0 $0 2025-02-14
Q3 2024 Unchanged 1,882 0 (0.0%) < 0.01% $5,646 2024-11-14
Q2 2024 Unchanged 1,882 0 (0.0%) < 0.01% $5,495 2024-08-14
Q1 2024 Unchanged 1,882 0 (0.0%) < 0.01% $6,445 2024-05-15
Q4 2023 Unchanged 1,882 0 (0.0%) < 0.01% $5,439 2024-02-13
Q3 2023 Reduced 0 -11,295 (-100.0%) 0 $0 2023-11-15
Q3 2023 New 1,882 +1,882 (0.0%) < 0.01% $5,239 2023-11-15
Q2 2023 Unchanged 11,295 0 (0.0%) < 0.01% $5,931 2023-08-14
Q1 2023 Unchanged 11,295 0 (0.0%) < 0.01% $5,195 2023-05-15
Q4 2022 Unchanged 11,295 0 (0.0%) < 0.01% $5,659 2023-02-14
Q3 2022 Reduced 11,295 -7,369 (-39.5%) < 0.01% $6,000 2022-11-14
Q2 2022 Reduced 18,664 -35,800 (-65.7%) < 0.01% $16,000 2022-08-15
Q1 2022 Added 54,464 +21,133 (63.4%) < 0.01% $66,000 2022-05-13
Q4 2021 Added 33,331 +18,582 (126.0%) < 0.01% $42,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

13 managers reported ACASTI PHARMA INC for Q4 2022.

Managers reporting ACASTI PHARMA INC in Q4 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
GEODE CAPITAL MANAGEMENT LLC Unchanged 18,348 0 < 0.01% $9,000 6 qtrs
NATIONAL BANK OF CANADA FI Added 18,418 +15,122 < 0.01% $8,856 5 qtrs
MORGAN STANLEY This report Unchanged 11,295 0 < 0.01% $5,659 6 qtrs
ROYAL BANK OF CANADA New 1,706 +1,706 < 0.01% $1,000 6 qtrs
MONEY CONCEPTS CAPITAL CORP New 187 +187 < 0.01% $94 1 qtr
Federation des caisses Desjardins du Quebec Unchanged 185 0 < 0.01% $89 6 qtrs
BlackRock Inc New 62 +62 < 0.01% $31 1 qtr
ICA Group Wealth Management LLC New 57 +57 < 0.01% $29 1 qtr
TD Waterhouse Canada Inc Unchanged 4 0 < 0.01% $3 3 qtrs
CONCOURSE FINANCIAL GROUP SECURITIES INC Unchanged 0 0 0 $0 6 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2022
Filed
February 14, 2023
Filing type
13F-HR
Position type
CL A

Voting authority reported

Sole
11,089
Shared
0
None
206

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.